- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04249245
Role of Nasal Dysbiosis in Parkinson Disease (SMELLPARK)
Study Overview
Detailed Description
Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such as microbial communities. Local inflammation induced by a nasal bacterial dysbiosis (microbiota imbalance) could lead to early neuronal dysfunctions in the olfactory system propagating in all the brain, thus inducing motor, cognitive and emotional manifestations in PD, in keeping with the Braak's stage hypothesis. We propose a translational project aiming at investigating the potential influence of nasal dysbiosis in PD pathogenesis. First, we will analyze both olfaction and nasal microbiota in a large series of PD patients and test the link between olfactory deficits and nasal dysbiosis. Then, we will take advantage of studying two populations of subjects with a very different environmental exposure (in mainland France and French West Indies) to isolate the abnormalities of the nasal microbiota that could be specific for PD. The study will be performed in 160 patients and 160 healthy volunteers. Patients will be enrolled in two investigators sites of which different environmental exposure: 1) Guadeloupe Hospital, French West Indies and 2) Pitie-Salpetriere Hospital, Paris, France. The patient selection will be conducted in consultation with the physician and it will be proposed to the spouse to participate as controls. The study subjects will be enrolled after collecting their informed consent.
As soon as the study subjects are included, the following measurements will be done at once at the inclusion:
- Neurological assessment: Idiopathic PD. Severity of the disease will be evaluated using the Hoehn and Yahr staging. Non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS). Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .
- Olfactory function: Olfactory performance will be measured using (a) the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and (b) a discrimination test of odorant mixtures developed by the Research Unit.
- Global cognitive performance and executive functions: The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance. Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.
- Memory: The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.
- Mood disorders: Two self-questionnaires will be used: the Snaith-Hamilton pleasure scale to assess anhedonia severity, and the Quick inventory of depressive symptomatology-self-rated for depression intensity evaluation. Two clinician rating tests for depression severity will also be used: the Hamilton Depression Rating Scale 17 and the MINI.
Sampling of human microbiota will be performed at the end. Subjects will undergo nasal brushing from anterior nares after local epinephrine application with a sterile flocked swab inserted and gently rolled around the inside of both nostrils. Swabs (one per nostril) will be placed on ice immediately after collection and then frozen at -80°C before shipment to the Research Unit (Institut Pasteur) where analyses will be carried out:
- Immunohistochemistry analysis: The levels of Neuroinflammation and aSyn proteins will be analyzed in the nasal tissue samples.
- Microbiome analysis: Microbial composition will be determined by metagenomic (pan-bacterial 16S rRNA gene sequencing).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Annie LANNUZEL, MD, PhD
- Phone Number: + 33 (0) 5 90 89 14 30
- Email: annie.lannuzel@chu-guadeloupe.fr
Study Contact Backup
- Name: Françoise LAZARINI, PhD
- Phone Number: + 33 (0) 1 44 38 92 74
- Email: francoise.lazarini-serandour@pasteur.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Pitie-Salpêtrière Hospital
-
Contact:
- Emmanuel ROZE, MD, PhD
- Email: emmanuel.flamand-roze@aphp.fr
-
-
-
-
-
Pointe-à-Pitre, Guadeloupe
- Not yet recruiting
- Centre Hospitalier Universitaire
-
Contact:
- Annie LANNUZEL, MD, PhD
- Email: annie.lannuzel@chu-guadeloupe.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients (PD)
- Age > 18 years
- Idiopathic PD
- In Guadeloupe (N=80) : living for more than 15 years in Caribbean, including the 5 first years.
- In Paris (N=80): living for more than 15 years in mainland France, including the 5 first years.
Controls
- Age > 18 years
- Spouse of enrolled PD patient or matched controls, with age difference between spouses <5 years. When the spouse cannot be included, a matched control respecting the PD group's final sex ratio and with an age difference <5 years relative to the concerned PD case will be enrolled.
Exclusion Criteria (both PD patients and controls)
- Presence of a cold or acute pathology which could explain an original olfactory disorder other than Parkinson's disease
- Use of nasal antiseptics within the last 3 months
- Refusal of or contraindication to nasal microbiota sampling
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parkinson Patients
These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris). They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015. |
All
|
Control Subjects
They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned. If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group. |
All
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial composition of the nasal swab samples based on 16S sequencing of DNA
Time Frame: 3 years
|
The operational taxonomic units (OTU) will be constructed and comparison between groups will be performed.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epidemiological characteristics of patients PD
Time Frame: 3 years
|
Demographic variables (locations of residence and types of housing), risk factors (activities, diet, history family).
|
3 years
|
Olfactory function
Time Frame: 3 years
|
Olfactory performance will be measured using the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and a discrimination test of odorant mixtures developed by the Research Unit
|
3 years
|
Neurological assessment: Idiopathic PD - Hoehn and Yahr staging.
Time Frame: 3 years
|
Severity of the disease will be evaluated using the Hoehn and Yahr staging.
|
3 years
|
Neurological assessment: Idiopathic PD - Non-Motor Symptoms Scale (NMSS)
Time Frame: 3 years
|
Severity of non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS).
|
3 years
|
Neurological assessment: Idiopathic PD - the Innsbruck REM sleep behaviour disorder inventory
Time Frame: 3 years
|
Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .
|
3 years
|
Global cognitive performance - MoCA
Time Frame: 3 years
|
The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance.
|
3 years
|
Executive functions
Time Frame: 3 years
|
Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.
|
3 years
|
Memory Function
Time Frame: 3 years
|
The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.
|
3 years
|
Mood disorders - the Snaith-Hamilton pleasure scale
Time Frame: 3 years
|
The Snaith-Hamilton pleasure scale (self-questionnaire) will be used to assess anhedonia severity,
|
3 years
|
Mood disorders - the Quick inventory of depressive symptomatology-self-rated
Time Frame: 3 years
|
The Quick inventory of depressive symptomatology-self-rated will be used for depression intensity evaluation.
|
3 years
|
Mood disorders - the Hamilton Depression Rating Scale 17
Time Frame: 3 years
|
The Hamilton Depression Rating Scale 17, a clinician rating test, will also be used to assess depression severity.
|
3 years
|
Mood disorders - the MINI
Time Frame: 3 years
|
The MINI, a clinician rating test, will also be used to assess depression severity.
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-030
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Nasal Swab
-
University of Colorado, DenverGlaxoSmithKlineCompletedFever | Influenza | Otitis Media | Lower Resp Tract Infection | Encephalitic Infection | Myositis ViralUnited States
-
Rigshospitalet, DenmarkRecruitingCOVID-19 | Influenza | RSV InfectionDenmark
-
LumiraDx UK LimitedActive, not recruitingCOVID-19United States
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
Assistance Publique Hopitaux De MarseilleCompletedInfective PericarditisFrance
-
Rush University Medical CenterCompletedParkinson DiseaseUnited States
-
University Hospital, CaenCompletedMicrobial Colonization | Neonatal Infection | Viral InfectionFrance
-
Public Health EnglandCompletedImmunization; InfectionUnited Kingdom
-
Hospices Civils de LyonCompleted
-
Centre Hospitalier Universitaire de BesanconUnknownStaphylococcus Aureus Nasal CarriageFrance